Pharvaris is developing oral bradykinin B2-receptor antagonists to provide effective prophylactic and on-demand treatment options for individuals with hereditary angioedema (HAE). This approach aims to eliminate the need for injections and reduce the frequency of HAE attacks, significantly improving patients' quality of life.
Funding
$300M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Hereditary angioedema (HAE) patients currently rely on injectable treatments for both prophylaxis and on-demand management of acute attacks, which can be inconvenient, painful, and may not always provide optimal control of symptoms. This can significantly impact their quality of life and create a need for more patient-friendly treatment options.
Solution
Pharvaris is developing a portfolio of novel, oral bradykinin B2-receptor antagonists designed to provide both prophylactic and on-demand treatment options for individuals living with HAE. By targeting the bradykinin pathway, Pharvaris's oral medications aim to prevent HAE attacks and effectively manage breakthrough symptoms without the need for injections. This approach offers the potential for improved convenience, reduced treatment burden, and enhanced overall management of HAE. The company's goal is to provide patients with greater freedom from HAE symptoms, attacks, and the limitations of injectable therapies.
Target Audience
The primary target audience includes individuals diagnosed with hereditary angioedema (HAE) who are seeking more convenient and less invasive treatment options. This also includes physicians specializing in the treatment of HAE.
Features
- Oral bradykinin B2-receptor antagonists for HAE treatment
- Development of both prophylactic and on-demand oral formulations
- Targeted approach to inhibit the bradykinin pathway and prevent HAE attacks
- Designed to eliminate the need for injections
- Aims to reduce the frequency and severity of HAE attacks